Dr. E. Shyam Reddy selected for International Goldstar Award 2012

Dr E. Shyam Reddy, GCC Distinguished Cancer Scholar, Professor and Co-Director of Cancer Biology Program, Dept of OB/GYN, Georgia Cancer Center for Excellence (10th Floor, Grady Hospital), Morehouse School of Medicine, Grady Health System, Atlanta, Ga.

Dr Reddy received the following awards:

  •  Selected to receive the prestigious International Goldstar Award, 2012
  •  To receive prestigious Best Personalities of India Award and Gold Medal, 2012
  •  Chosen to receive the prestigious Bharat Excellence Award and Gold Medal, 2012 by FFI
  •  Selected to receive the prestigious Super Achievers of India Award and Gold Medal, 2012
  •  CPDR Saturday Distinguished Visiting Professor, 2011 .
Short Biography
Dr Reddy carriedout his Ph.D. work at the Center for Cellular and Molecular  Biology, Hyderabad, India (Dr PM. Bhargava). Part of Ph.D. work was carriedout at Max Planck Institute for Biophysical Chemistry, Gottingen, West Germany (Prof. K.H. Scheit). His Ph.D. work was published as two papers in the prestigious Nature journal for which he was awarded National  Young Scientist award by the Prime minister of India. Dr Reddy received First Margaret Memorial award, UK to carryout research at NIH. He obtained postdoctoral training in molecular biology at Yale University, CT (Dr Weissman’s laboratory) (National Academy member).

            Later,  Dr Reddy moved to NCI-Frederick cancer Facility to take his first independent scientist job, where he  discovered novel  genes, named ERG-1 and ERG-2 (Dr Reddy named them as ETS Related Gene )  (published in  the prestigious Science and PNAS journals in collaboration with Late Dr Papas).  This gene is involved in 40-80% of Prostate cancers and also in Ewing sarcoma (Children bone cancer) and leukemias. Dr Reddy group have shown that ERG gene products function as  sequence specific DNA binding proteins and act as transcriptional activators. Dr Reddy then moved to Wistar Institute and Temple University (along with the cancer center director Dr Croce), Philadelphia as assistant and associate professor where they identified ELK-1 gene (published in prestigious Science journal in collaboration with Dr Rao and Dr Croce). Dr Reddy and Dr Rao named the gene as ELK-1 (standing for ETS Like Gene). ELK-1 plays a central role in Signal Transduction.

Later, Dr Reddy joined  Thomas Jefferson University (along with the rest of cancer center faculty, 1991 ) where his group discovered and identified the function of several cancer causing genes human Fli-1, EWSb, TLS/FUS, EWS-Fli-1, EWS-erg, TLS-erg, EWS-ATF-1 and  tumor suppressor gene BRCA2a. In collaboration with Dr Rao, he also identified BRCA1a and BRCA1b (Patented). Dr Rao and Dr Reddy are the first investigators to show that BRCA1 proteins  induce apoptosis (cell death program) and also first to show a regulatory aspect to BRCA1 nuclear ⁄ non-nuclear distribution. BRCA1 gene plays a central role in breast and ovarian cancers. Dr Reddy, Rao  and his colleagues are also the first one to show Fli-1 and erg proteins (and it’s abnormal  fused proteins) inhibit cell death program (apoptosis).

Dr Reddy joined Drexel university/ Hahnemann University  (1996) as Professor and Director, Program of Cancer Genetics. Here, Dr Reddy and his colleagues have shown that aberrant ERG and Fli-1 proteins (involved in several cancers inclding Ewing sarcoma, Prostate cancer and leukemias) are responsible for making cancer cells resistant to chemo-therapeutic agents. They also discovered BRCA2a involved in breast cancer. Because of chapter 11 status of Medical school, Dr Reddy decided to look for a different stable organization in 2002.

Dr Reddy was appointed  as a chairman of Pharmacy school at NDSU (2002). Because of personal family reasons, Dr Reddy decided  to join Morehouse School of Medicine as Professor and Co-Director, Cancer Biology Program (2002) (instead of chairman position at NDSU). Here, Dr Reddy and his colleagues developed novel cell based assay to detect erg/ets function and identified several novel anticancerous therapeutic agents. Some of these therapeutic agents  target erg and other abnormal erg/Fli-1/ets protein function (patent pending). Dr Reddy is studying the mechanism of action of these novel therapeutic agents and also testing them at preclinical level. He received GCC Distinguished Cancer Scholar award from the Governor of Georgia to carryout his cancer research work.

Dr Reddy and his group have recently discovered novel POST-TRANSLATIONAL mechanism in breast cancer cells that will have global effect on the Gene Expression, Differentiation, Protein turnover, Cell Death, Cancer and other Human diseases. Dr Reddy predicts that this CBP/p300-mediated post-translational modification may be a signal for degradation/ turnover of CBP interacting proteins.

To know more follow this link : http://www.reddyesp.com